skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

The enactment of the US FDA Biosimilar 351(k) pathway in March 2010 has created uncertainty on many fronts. The innovator, biosimilar developer, FDA, and payer have spent years readjusting their strategies to prepare for the introduction of biosimilars in the US. BioMedTracker’s recent Biosimilars Special Report characterizes the biosimilar environment through a discussion of biosimilar development, regulatory pathways, reimbursement, and an analysis of US partnerships deals.

 

 

On the regulatory front, the Report begins by providing an evaluation of relevant analytical techniques that reveal structural variability between a biosimilar and its reference product. The US regulatory pathways to approval are then outlined and discussed as industry awaits FDA guidance regarding the “Interchangeable” designation. This designation is unique to the US and would bridge the gap between biosimilars and their generic cousins. The Biosimilar Special Report follows with a data driven discussion of the development timeline of biosimilars vs. standard biologics. Data has shown that the biosimilar 351(k) pathway does in fact offer an expedited pathway to approval through the reduction of Phase I and Phase III requirements, and forgone Phase II studies. BioMedTracker estimates a difference of 3.37 years for Phase I to Phase III development between biosimilars and standard biologics.

 

 

The Biosimilars Special Report also delvesinto the partnering landscape by analyzing its primary observation of deals concerning US biosimilars. Results first show that partnerships for US biosimilars were predominantly initiated during US preclinical development (56%), which confirms the advantage of early partnerships for biosimilar development. By partnering at the discovery phase, large cap companies can use their resources to focus on marketing, while small cap and foreign companies can focus on the discovery of biosimilars, thereby leveraging each company’s individual strengths. Of the seven biosimilars partnerships that began prior to US development, all have progressed to Phase III or an approval filing to the FDA. Not only can ex-US data build a stronger case for approval, but US companies can also utilize the experience of emerging market companies that are familiar with biosimilar development. It is therefore advantageous for companies to partner early in the US or while development is ex-US.

 

 

On the payer side, one-on-one interviews with reimbursement experts and industry research have revealed that payers are highly receptive to the introduction of biosimilars. Payers anticipate price and rebate discussions from the biosimilar for formulary inclusion and from the brand to maintain formulary access. One KOL interview suggested that price reduction of at least 20%, including rebates, would be required to make the formulary disruption worthwhile. Upon agreement, payers are prepared to use formulary management tools like tiering, step-therapy, and prior authorization to encourage the uptake of biosimilars.

 

For the complete report, visit BioMedTracker.

お問い合わせ&レポートストア

専任スタッフによるデモンストレーションを兼ねたサービスの詳しいご説明、または無料トライアルを常時受け付けています。ご希望の場合は下記のフォームよりお気軽にお申し込みください。

*一部のサービスでは無料トライアルをご利用になれません。

ご質問等ございましたらお気軽にご連絡下さい。

日本(平日:9時~18時)
電話:+81 (0)3 6273 4260
Email:inquiry.jp@informa.com

オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。

お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。